192 related articles for article (PubMed ID: 32429078)
1. Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival.
Mansouri H; Alcaraz LB; Mollevi C; Mallavialle A; Jacot W; Boissière-Michot F; Simony-Lafontaine J; Laurent-Matha V; Roger P; Liaudet-Coopman E; Guiu S
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429078
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
Guiu S; Mollevi C; Charon-Barra C; Boissière F; Crapez E; Chartron E; Lamy PJ; Gutowski M; Bourgier C; Romieu G; Simony-Lafontaine J; Jacot W
Br J Cancer; 2018 Jul; 119(1):76-79. PubMed ID: 29880907
[TBL] [Abstract][Full Text] [Related]
6. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
Riaz N; Idress R; Habib S; Lalani EN
Front Oncol; 2020; 10():1083. PubMed ID: 32850312
[No Abstract] [Full Text] [Related]
7. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
8. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X
Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676
[TBL] [Abstract][Full Text] [Related]
9. A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.
Alcaraz LB; Mallavialle A; David T; Derocq D; Delolme F; Dieryckx C; Mollevi C; Boissière-Michot F; Simony-Lafontaine J; Du Manoir S; Huesgen PF; Overall CM; Tartare-Deckert S; Jacot W; Chardès T; Guiu S; Roger P; Reinheckel T; Moali C; Liaudet-Coopman E
Theranostics; 2021; 11(13):6173-6192. PubMed ID: 33995652
[No Abstract] [Full Text] [Related]
10. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis.
Wang C; Pan B; Zhu H; Zhou Y; Mao F; Lin Y; Xu Q; Sun Q
Oncotarget; 2016 Jul; 7(29):46482-46491. PubMed ID: 27374089
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study.
Bhattarai S; Klimov S; Mittal K; Krishnamurti U; Li XB; Oprea-Ilies G; Wetherilt CS; Riaz A; Aleskandarany MA; Green AR; Ellis IO; Cantuaria G; Gupta M; Manne U; Agboola J; Baskovich B; Janssen EAM; Callagy G; Walsh EM; Mehta A; Dogra A; Shet T; Gajaria P; Traina T; Nggada HA; Omonisi A; Ahmed SA; Rakha EA; Rida P; Aneja R
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31319547
[TBL] [Abstract][Full Text] [Related]
14. Association between androgen receptor status and prognosis in triple negative breast cancer.
Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.
Adamo B; Ricciardi GRR; Ieni A; Franchina T; Fazzari C; Sanò MV; Angelico G; Michele C; Tuccari G; Adamo V
Oncotarget; 2017 Sep; 8(44):76974-76986. PubMed ID: 29100362
[TBL] [Abstract][Full Text] [Related]
16. Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer.
Asano Y; Kashiwagi S; Goto W; Tanaka S; Morisaki T; Takashima T; Noda S; Onoda N; Ohsawa M; Hirakawa K; Ohira M
Cancers (Basel); 2017 Jan; 9(1):. PubMed ID: 28067809
[TBL] [Abstract][Full Text] [Related]
17. Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?
Dubrava AL; Kyaw PSP; Newman J; Pringle J; Westhuyzen J; La Hera Fuentes G; Shakespeare TP; Sakalkale R; Aherne NJ
Breast Cancer (Dove Med Press); 2023; 15():359-371. PubMed ID: 37197610
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and Clinical Significance of PD-L1, EGFR and Androgen Receptor (AR) Expression in Triple-Negative Breast Cancer (TNBC) Patients.
Medić-Milijić N; Jovanić I; Nedeljković M; Marković I; Spurnić I; Milovanović Z; Ademović N; Tomić T; Tanić N; Tanić N
Life (Basel); 2024 May; 14(6):. PubMed ID: 38929666
[TBL] [Abstract][Full Text] [Related]
19. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Abd-Elazeem MA; Abd-Elazeem MA
Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
[TBL] [Abstract][Full Text] [Related]
20. Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
Sang M; Meng L; Ma C; Liu S; Sang M; Chang S; Liu F; Lian Y; Geng C
Biomed Pharmacother; 2019 Mar; 111():169-177. PubMed ID: 30580238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
